Drilldown: Medicines
More actions
Medicines > classes 
:
Antidepressant or
Phenethylamine or
[[:Category:Anti-inflammatories|Anti-inflammatory]]
:
Antidepressant or
Phenethylamine or
[[:Category:Anti-inflammatories|Anti-inflammatory]] Use the filters below to narrow your results.
generic:
brand:
None (26) ·
Anafranil (1) ·
Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) (1) ·
Aurorix (1) ·
Colcrys, Mitigare, Gloperba, Lodoco (low-dose cardiovascular) (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) ·
Norpramin (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (44) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1) ·
'"`UNIQ--vote-00000C6D-QINU`"', '"`UNIQ--vote-00000C6E-QINU`"', '"`UNIQ--vote-00000C6F-QINU`"', '"`UNIQ--vote-00000C70-QINU`"', '"`UNIQ--vote-00000C71-QINU`"' (1)
starting dose:
None (44) ·
25 mg (1) ·
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1) ·
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction (1)
preparations:
fda max:
routes:
onset:
None (42) ·
45-75 min (oral) (1) ·
Anti-inflammatory effect within 24 hours of gout flare onset; loses effectiveness if delayed (1) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Symptomatic improvement 2-4 weeks (1)
duration:
halflife:
None (42) ·
Not well characterized (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~27-31 hours; markedly prolonged in renal/hepatic impairment and with CYP3A4 or P-gp inhibitors'"`UNIQ--ref-00000C72-QINU`"' (1) ·
~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1)
bioavailability:
None (42) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1) ·
Not well characterized (1) ·
~45% (oral)'"`UNIQ--ref-00000C73-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (42) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not established (1) ·
Used in FMF in pregnancy; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 47 results in range #1 to #47.